Changchun High-Tech's Unit Gets Nod to Trial Menopausal Vasomotor Syndrome Drug in US

MT Newswires Live

2024/12/24

Changchun High-Tech Industry Group's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, received implied approval from the US Food and Drug Administration for the clinical trial of the menopausal vasomotor syndrome drug, GS1-144, according to a Shenzhen Stock Exchange disclosure on Tuesday.

The biopharmaceutical company is allowed to begin clinical trials for the drug after the application for the phase II clinical trials reached the regulator's implicit approval period, the filing said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2493723784"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493723784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2493723784?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-24 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493723784","market":"sh","top_or_hot":-1,"title":"Changchun High-Tech's Unit Gets Nod to Trial Menopausal Vasomotor Syndrome Drug in US","media":"MT Newswires Live","content":"<html><body><p> Changchun High-Tech Industry Group's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, received implied approval from the US Food and Drug Administration for the clinical trial of the menopausal vasomotor syndrome drug, GS1-144, according to a Shenzhen Stock Exchange disclosure on Tuesday.</p><p>The biopharmaceutical company is allowed to begin clinical trials for the drug after the application for the phase II clinical trials reached the regulator's implicit approval period, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech's Unit Gets Nod to Trial Menopausal Vasomotor Syndrome Drug in US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech's Unit Gets Nod to Trial Menopausal Vasomotor Syndrome Drug in US\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-12-24 11:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Changchun High-Tech Industry Group's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, received implied approval from the US Food and Drug Administration for the clinical trial of the menopausal vasomotor syndrome drug, GS1-144, according to a Shenzhen Stock Exchange disclosure on Tuesday.</p><p>The biopharmaceutical company is allowed to begin clinical trials for the drug after the application for the phase II clinical trials reached the regulator's implicit approval period, the filing said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493723784","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493723784","pubTimestamp":1735011222,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Changchun High-Tech Industry Group's  unit, Changchun Jinsai Pharmaceutical, received implied approval from the US Food and Drug Administration for the clinical trial of the menopausal vasomotor syndrome drug, GS1-144, according to a Shenzhen Stock Exchange disclosure on Tuesday.The biopharmaceutical company is allowed to begin clinical trials for the drug after the application for the phase II clinical trials reached the regulator's implicit approval period, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0046":"生物疫苗","BK0028":"国家队","BK0057":"长吉图板块","BK0239":"医药制造","000661":"长春高新","BK0075":"新三板","BK0188":"融资融券"},"translate_title":"长春高新子公司获准在美国试验治疗更年期血管舒缩综合征药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000661":0.9},"content_text":"Changchun High-Tech Industry Group's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, received implied approval from the US Food and Drug Administration for the clinical trial of the menopausal vasomotor syndrome drug, GS1-144, according to a Shenzhen Stock Exchange disclosure on Tuesday.The biopharmaceutical company is allowed to begin clinical trials for the drug after the application for the phase II clinical trials reached the regulator's implicit approval period, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}